An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants

NCT00613327 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

345

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: Oxybutynin chloride OROS

Sponsor

Janssen Korea, Ltd., Korea